We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Few Diabetics Meet Treatment Goals

By HospiMedica staff writers
Posted on 02 Feb 2004
A study has found that fewer than 12% of diabetics meet the recommended goals for blood glucose, blood pressure, and cholesterol, all of which have been proven to delay or prevent diabetes complications. More...
Moreover, this percentage has not changed much in the last decade. The findings were reported in the January 21, 2004, issue of the Journal of the American Medical Association (JAMA).

Researchers compared data obtained from a sample of adults age 20 and older with diagnosed diabetes who took part in a national study conducted from 1988-1994 or another one conducted from 1999 to 2000. Those who participated in the later study, though similar in weight and gender, were heavier, diagnosed with diabetes younger, and more likely to be using insulin. Only 37% were achieving the desired blood glucose control and only 36% met the current blood pressure goal of less than 130/80 mmHg. Also, more participants in the later study were receiving medicine to lower high cholesterol. Diabetes is the main cause of kidney failure, limb amputation, and new onset blindness in adults and also a major cause of heart disease and stroke.

"We must redouble our efforts to empower patients and providers with information and tools to improve therapy and to provide incentives for the comprehensive care that has been proven effective in reducing diabetes complications,” said coauthor Dr. Judith Fradkin, director of the Diabetes, Endocrinology, and Metabolic Diseases division of the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).




Related Links:
NIDDK

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.